Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FBM Reduced-Intensity Conditioning for MDS Allo-HCT
NCT07085156Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, melphalan, busulfan in myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
fludarabinemelphalanbusulfan
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07085156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085156.